OPKO Health (OPK) Advances EBV Vaccine and GLP-1 Pipeline While Streamlining Diagnostics

We recently published 12 Best Healthcare Stocks to Buy Under $30. OPKO Health, Inc. (NASDAQ:OPK) is one of the best healthcare stocks.

OPKO Health, Inc. (NASDAQ:OPK) is a diversified healthcare company with operations in diagnostics, pharmaceuticals, and innovative therapies, anchored by BioReference Laboratories and an expanding drug development pipeline. The company is advancing programs in immunology, endocrinology, oncology, and metabolic disorders through both internal research and strategic collaborations.

In 2025, OPKO Health, Inc. (NASDAQ:OPK) made notable progress across multiple fronts. In partnership with Merck, it is advancing a Phase 1 trial for an experimental Epstein-Barr virus (EBV) vaccine, which could move to Phase 2 pending trial results. Its metabolic disease pipeline includes OPK-88006, an investigational oral GLP-1/glucagon dual agonist for obesity and metabolic-associated steatohepatitis (MASH). Data presented at ENDO 2025 demonstrated strong bioavailability and efficacy, with both oral and weekly injectable formats in development.

The company is also working with Entera Bio on an oral GLP-2 agonist for short bowel syndrome, with promising PK/PD data set for presentation at the 2025 ESPEN Congress. In oncology, the business’s subsidiary ModeX is developing multispecific antibody therapeutics, with four clinical candidates, including lymphoma and leukemia treatments, targeting a range of solid tumors and blood cancers, and human trials expected to begin in early 2026.

OPKO Health (OPK) – OPKO Advances EBV Vaccine and GLP-1 Pipeline While Streamlining Diagnostics

Photo by National Cancer Institute on Unsplash

On the diagnostics front, the FDA approved a key update to OPKO’s 4KScore Test, allowing use without digital rectal examination data, broadening its role in primary care for prostate cancer risk assessment. Additionally, the planned sale of certain BioReference oncology and clinical testing assets to Labcorp, expected to close in late 2025, will allow OPKO Health, Inc. (NASDAQ:OPK) to sharpen its focus on core diagnostics and pharmaceuticals while improving operational efficiency.

While we acknowledge the risk and potential of OPK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than OPK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.